CCE - Coca-Cola Enterprises Inc
CTAS - Cintas Corporation
EPB - El Paso Pipeline Partners, LLC
HEP - Holly Energy Partners, LP
LINE - Linn Energy, LLC
MOLX - Molex Incorporated
NS - Nustar Energy Lp
PH - Parker-Hanniforn Corp
PRE - PartnerRe Ltd
RCI - Rogers Communications, Inc
STRA - Strayer Education, Inc
AEP - American Electric Power - There is nothing particularly interesting with this stock base on our model. It is ok.
CCE - Coca-Cola Enterprises Inc - OK, so this stock isn't exciting, nut overall the profile is attractive. Low RVI, the Dec option captures the dividend.
CTAS - Cintas Corporation - Again nothing exciting. Either date gets the dividend and the RVI's are ok.
EPB - El Paso Pipeline Partners, LLC - RVI's are high and obviously this stock is trading rich to the last year. Ex-date was last Friday so if you don't own the stock don't plan on getting paid.
HEP - Holly Energy Partners, LP - Near date Day's earnings are great. The next date is February.
LINE - Linn Energy, LLC - P/E, what P/E? RVI's are high as they near dated Day's earning.
MOLX - Molex Incorporated - Boring?
NS - Nustar Energy Lp - Check out this profile. The far dated expiration is March! The days earning's look pretty good too....
PH - Parker-Hanniforn Corp - High RVI's and both earn the dividend.
PRE - PartnerRe Ltd - Near date looks good and the RVI's are rich but not extreme.
RCI - Rogers Communications, Inc - Boring? Heck yah but it is what we like..... The dividend pays at both near and far dates.
STRA - Strayer Education, Inc - Based on our model this stock is a screaming buy. Low P/E, high dividend, high SSR and Days earning. Did I mention the low RVI?
*Note: the tables shown are embedded .jpg files. This means that you can: 1) double left click them with your mouse to enlarge them, or 2) right click them with your mouse and choose to open them in a new window or tab, print, save, etc.
As with everything we post, we may or may not have the stock and/or strategy in place in any one of our portfolios or may add it at any time. We do not make any buy or sell recommendations. We provide basic analytical research, some short commentary of the results and encourage you to do your own thorough due diligence prior to any purchase or sale.














